Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043548 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
A Phase 2 study of Dermatomyositis and Polymyositis, sponsored by Chester Oddis.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 7
- Study locations
NCT02043548 is a Phase 2 study of Dermatomyositis and Polymyositis that has completed, run by Chester Oddis. The registered enrollment target is 36 participants, below the 483-participant average among 19 other Dermatomyositis trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT02043548, a Phase 2 study of Dermatomyositis and Polymyositis, has completed, sponsored by Chester Oddis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this multi-center pilot study is to determine if the drug tocilizumab (Actemra) is effective in the treatment of patients with refractory adult polymyositis (PM) and dermatomyositis (DM).
Conditions Studied
Interventions
- DRUG placebo
- DRUG tocilizumab
Study Locations (7)
California
- Cedars Sinai Medical Center - Los Angeles
Kansas
- University of Kansas Medical Center - Kansas City
Minnesota
- Mayo Clinic - Rochester
New York
- North Shore Long Island Jewish Center - Great Neck
Pennsylvania
- University of Pittsburgh - Pittsburgh
Tennessee
- Vanderbilt University - Nashville
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-10-01 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043548
The ClinicalTrials.gov registry entry for NCT02043548 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 19 other Dermatomyositis trials with a reported enrollment target (93% lower). The listed sponsor is Chester Oddis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dermatomyositis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02043548 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Kansas, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02043548 about?
NCT02043548 is a clinical study titled "Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis". The purpose of this multi-center pilot study is to determine if the drug tocilizumab (Actemra) is effective in the treatment of patients with refractory adult polymyositis (PM) and dermatomyositis (DM).
What is the current status of trial NCT02043548?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-10-01. Estimated completion is 2019-07-31.
What conditions does trial NCT02043548 study?
This clinical trial studies the following conditions: Dermatomyositis, Polymyositis.
What interventions are being tested in trial NCT02043548?
The interventions under investigation include: placebo (DRUG), tocilizumab (DRUG).
Who is sponsoring clinical trial NCT02043548?
This trial is sponsored by Chester Oddis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02043548 being conducted?
This trial has 7 study locations across California, Kansas, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
RECRUITING · Phase 2
-
Intralesional Injection of STS in Treatment of Calcinosis
RECRUITING · Phase 2
-
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.